Skip to content
Search

Latest Stories

MHRA approves Moderna Covid-19 vaccine for 12 to 17-year-olds

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the Moderna Covid-19 vaccine for children aged 12 to 17, after previously giving the green light to Pfizer.

The medicines watchdog said in a statement on Aug 17 that the jab was "safe and effective in this age group".


But it added it would now be up to government advisory body the Joint Committee on Vaccination and Immunisation (JCVI) to recommend whether to start giving the jab.

Britain began its mass vaccination programme in December last year and has to date seen nearly 90 percent of all adults receive a first dose.

More than three-quarters (77 per cent) have had two doses -- a factor in the government lifting all remaining legal coronavirus restrictions in England on Monday.

Health officials say vaccination has contributed to a fall in hospital admissions with more serious cases of Covid, even though infection rates have risen.

Earlier this month, the government said it would offer jabs to all 16 and 17 year olds but unlike other countries, held off rolling out the programme to younger children.

The JCVI said only 12 to 15 year olds deemed vulnerable should receive a vaccine -- a more cautious approach than in the United States and the European Union.

They, as with older teens that are eligible, are being given the Pfizer/BioNTech shot.

The government has set a target of giving a first dose to 16 and 17 year olds by August 23, to give them some protection before the start of school in England and Wales in September.

Dr June Raine, MHRA Chief Executive, said: "I am pleased to confirm that that the Covid-19 vaccine made by Moderna has now been authorised in 12-17 year olds. The vaccine is safe and effective in this age group.

"We have in place a comprehensive safety surveillance strategy for monitoring the safety of all UK-approved Covid-19 vaccines and this surveillance will include the 12- to 17-year age group.

"It is for the Joint Committee on Vaccination and Immunisation (JCVI) to advise on whether this age group should be vaccinated with the Covid-19 vaccine made by Moderna as part of the deployment programme."

More For You

Pharmacist handing medicine to patient, NHS prescription cost freeze debate

Prescription charge will remain at £9.90

Pic credit: iStock

NPA calls for end to prescription charge after freeze announcement

The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.

Patients will continue paying £9.90 to collect their medication from a pharmacy.

Keep ReadingShow less
RPS launches new prescribing development programme for pharmacists

From 2026, every newly qualified pharmacist will be an independent prescriber

gettyimages

RPS unveils new training programme to enhance pharmacists’ prescribing skills

The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.

Keep ReadingShow less
Varenicline promotes nicotine vaping cessation in young people

Researchers warn that e-cigarette use can increase risk for nicotine addiction,uptake of combusted tobacco and other substance use.

gettyimages

Anti-smoking pill varenicline may help young people quit vaping, new study suggests

Varenicline — a daily pill already offered through NHS Stop Smoking Services — could also support young people in quitting vaping, new research has suggested.

The medication, proven to be more effective than nicotine replacement gums or patches for smoking cessation, was shown to significantly boost vaping abstinence when combined with behavioural counselling in adolescents and young adults.

Keep ReadingShow less
Relying on blue inhalers alone can worsen asthma symptoms, warns MHRA

Patients are advised to use their preventer inhaler regularly, even if their asthma feels under control.

Pic credit: gettyimages

Overuse of blue inhalers can increase risk of severe asthma attacks, warns MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding asthma patients to use their preventer (anti-inflammatory) inhalers regularly as prescribed, rather than relying solely on their blue inhalers, also referred to as reliever inhalers.

“Without regular use of a preventer inhaler, symptoms could worsen and increase the risk of severe asthma attacks,” the MHRA warned.

Keep ReadingShow less
13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less